Novel Peptide Targets Both Appetite and Metabolism Through Combined MC4 and GLP-1 Receptor Activation
A single peptide combining melanocortin-4 and GLP-1 receptor agonism showed improved weight loss and metabolic outcomes with better tolerability than GLP-1 alone in preclinical models.
Quick Facts
What This Study Found
A monomeric peptide combining MC4 and GLP-1 receptor agonism showed enhanced weight loss and metabolic benefits with improved tolerability in preclinical models.
Key Numbers
How They Did This
Peptide design fusing α-MSH and Exendin-4 sequences, followed by in vitro receptor activation assays and in vivo metabolic studies in animal models.
Why This Research Matters
Better-tolerated obesity drugs are urgently needed, especially for children and adolescents. Dual MC4/GLP-1 targeting could provide a new pathway to effective, tolerable weight loss therapy.
The Bigger Picture
Beyond dual GIP/GLP-1 agonists (tirzepatide), multi-target peptides incorporating appetite-regulatory pathways like MC4 represent the next frontier in obesity pharmacotherapy.
What This Study Doesn't Tell Us
Preclinical data only — animal models may not predict human efficacy or tolerability; single peptide design challenges for manufacturing and stability.
Questions This Raises
- ?Will the improved tolerability translate to human trials?
- ?How does MC4/GLP-1 dual targeting compare to GIP/GLP-1 dual agonism?
Trust & Context
- Key Stat:
- Dual MC4 + GLP-1 agonism Single peptide targets two pathways for enhanced weight loss with improved tolerability
- Evidence Grade:
- Preclinical animal study — promising proof-of-concept but years from potential clinical use.
- Study Age:
- Published 2026 in Metabolism.
- Original Title:
- A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.
- Published In:
- Metabolism: clinical and experimental, 174, 156414 (2026)
- Authors:
- Ashlaw, Emily F(2), Elfers, Clinton T(2), Chichura, Kylie S(3), Miranda, Isabella Chavez, McGivney, Aelish, Chepurny, Oleg G, Holz, George G, Mullins, Ginger, den Hartigh, Laura J, Liu, Yongjun, Roth, Christian L, Doyle, Robert P
- Database ID:
- RPEP-14793
Evidence Hierarchy
Frequently Asked Questions
What is MC4 receptor targeting?
The melanocortin-4 receptor is a brain receptor that controls appetite and energy balance. Activating it reduces hunger. Combining MC4 targeting with GLP-1 activation may produce better weight loss with fewer GI side effects.
Could this replace current weight loss drugs?
It's too early to say — this is a promising preclinical finding. If it works in human trials, it could offer a better-tolerated alternative to current GLP-1-only approaches, particularly for younger patients.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14793APA
Ashlaw, Emily F; Elfers, Clinton T; Chichura, Kylie S; Miranda, Isabella Chavez; McGivney, Aelish; Chepurny, Oleg G; Holz, George G; Mullins, Ginger; den Hartigh, Laura J; Liu, Yongjun; Roth, Christian L; Doyle, Robert P. (2026). A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.. Metabolism: clinical and experimental, 174, 156414. https://doi.org/10.1016/j.metabol.2025.156414
MLA
Ashlaw, Emily F, et al. "A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.." Metabolism: clinical and experimental, 2026. https://doi.org/10.1016/j.metabol.2025.156414
RethinkPeptides
RethinkPeptides Research Database. "A melanocortin 4- and glucagon-like peptide 1 receptor multi..." RPEP-14793. Retrieved from https://rethinkpeptides.com/research/ashlaw-2026-a-melanocortin-4-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.